Valuation: Natera, Inc.

Market Cap 45.24B 40.57B 37.39B 33.96B 64.26B 4,241B 66.06B 448B 178B 2,272B 170B 166B 7,184B P/E 2026 *
-204x
P/E 2027 * -715x
Enterprise Value 44.18B 39.62B 36.52B 33.16B 62.76B 4,142B 64.51B 437B 174B 2,219B 166B 162B 7,016B EV / Sales 2026 *
14.7x
EV / Sales 2027 * 12x
Free-Float
97.12%
Yield 2026 *
-
Yield 2027 * -
1 day-2.62%
1 week-19.72%
Current month-24.70%
1 month-22.14%
3 months-2.00%
6 months+60.62%
Current year+36.18%
1 week 304
Extreme 304
379.5
1 month 304
Extreme 304
436.19
Current year 181
Extreme 181
437.41
1 year 181
Extreme 181
437.41
3 years 46.96
Extreme 46.96
437.41
5 years 26.1
Extreme 26.1
437.41
10 years 7.35
Extreme 7.35
437.41
Manager TitleAgeSince
Chief Executive Officer 43 05/11/2026
President 46 01/09/2023
Director of Finance/CFO 45 01/02/2017
Director TitleAgeSince
Chairman 53 01/05/2015
Director/Board Member 53 01/01/2007
Director/Board Member 43 05/11/2026
Date Insider Type Main position Quantity % Market Cap. Importance
11/3/26 A Sell

Chief Financial Officer

-470 0.0003%
11/2/26 A Sell

Founder

-341 0.0002%
11/2/26 A Sell

Chief Executive Officer

-3,419 0.0024%
Change 5-day change 1-year change 3-year change Capi.($)
-2.62%-19.72%+50.98%+567.48% 45.24B
+4.41%-2.63%+14.79%+31.52% 114B
-0.09%+8.98%+9.82%+116.66% 105B
+0.11%+9.55%+11.61%+113.54% 33.58B
-0.26%+4.79%+42.03%+81.11% 30.12B
-0.47%+4.61%+40.22%+94.58% 28.43B
+0.44%+8.84%+49.10%+439.64% 23.1B
+0.23%+2.73%-17.74%-15.87% 20.02B
-0.65%-1.16%-7.35%+30.12% 16.86B
+4.83%+3.79%+115.94% - 15.1B
Average +0.59%+1.52%+30.94%+162.09% 43B
Weighted average by Cap. +1.00%+1.11%+23.70%+146.05%

Financials

2026 *2027 *
Net sales 3.01B 2.7B 2.48B 2.26B 4.27B 282B 4.39B 29.74B 11.85B 151B 11.28B 11.04B 477B 3.65B 3.27B 3.01B 2.74B 5.18B 342B 5.32B 36.07B 14.37B 183B 13.68B 13.39B 579B
Net income -223M -200M -184M -167M -316M -20.87B -325M -2.2B -877M -11.18B -835M -818M -35.34B -53.93M -48.37M -44.58M -40.48M -76.62M -5.06B -78.76M -534M -213M -2.71B -202M -198M -8.56B
Net Debt -1.06B -947M -873M -793M -1.5B -99.05B -1.54B -10.45B -4.17B -53.07B -3.96B -3.88B -168B -1.37B -1.23B -1.13B -1.03B -1.95B -129B -2.01B -13.59B -5.41B -68.98B -5.15B -5.04B -218B
Projected Income Statement - Annual - Natera, Inc.
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
10/11/26 $311.98 -2.62% 1,751,255
09/11/26 $320.39 +3.13% 2,784,479
06/11/26 $310.67 -14.59% 5,777,243
05/11/26 $363.76 -6.97% 3,234,626
04/11/26 $391.03 +0.62% 2,800,572
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
MarketScreener Ratings - Natera, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
311.98USD
Average target price
410.02USD
Spread / Average Target
+31.43%
  1. Stock Market
  2. Stocks
  3. NTRA Stock